Clinical trial
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing…
NCT00208312 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00208312 |
|---|---|
| Title | ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) |
| Official title | A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging |
| Lead sponsor | Gilead Sciences, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | Regadenoson, Adenosine |
| Enrollment | 787 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 26, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: